HamodaHPanayNPedderH, et al.The British menopause society & women’s health concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health2020; 26: 181–209.
2.
AnagnostisPBosdouJKVaitsiK, et al.Estrogen and bones after menopause: A reappraisal of data and future perspectives. Hormones (Athens)2021; 20: 13–21, Springer Nature Link.
3.
KuhlH. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climateric2005; 8: 3–63.
4.
AlbertazziPPurdiDW. The life and times of the estrogen receptors: an interim report. Climacteric2001; 4: 194–202.
5.
DeliTOroszMJakabA. Hormone replacement therapy in cancer survivors - review of the literature. Pathol Oncol Res2020; 26: 63–78.
6.
FrickKMZhaoZFanL. The epigenetics of estrogen: epigenetic regulation of hormone-induced memory enhancement. Epigenetics2011; 6: 675–680.
7.
BorrásMHardyLLempereurF, et al.Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol1994; 48(4): 325–336.
8.
RosnerWHankinsonSESlussPM, et al.Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab2013; 98: 1376–1387.
9.
SkibaMABellRJIslamRM, et al.Androgens during the reproductive years: what is normal for women?J Clin Endocrinol Metab2019; 104: 5382–5392.
10.
DeecherDCDorriesK. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Wom Ment Health2007; 10: 247–257.
11.
ReddyNDesaiMNSchoenbrunnerA, et al.The complex relationship between estrogen and migraines: a scoping review. Syst Rev2021; 10(1): 72.
12.
GordonJLPeltierAGrummischJA, et al.Estradiol fluctuation, sensitivity to stress, and depressive symptoms in the menopause transition: a pilot study. Frontiers in Pyschology2019; 10: 1319.
13.
TepperPGRandolphJFJrMcConnellDS, et al.Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the study of women’s health across the nation (SWAN). J Clin Endocrinol Metab2012; 97: 2872–2880.
14.
LaingAHillardT. Estrogen-based therapies for menopausal symptoms. Best Pract Res Clin Endocrinol Metabol2024; 38: 101789.
15.
O’ConnellMB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol1995; 35(9S): 18S–24S.
16.
StanczykFZShoupeDNunezV, et al.A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol1988; 159: 1540–1546.
17.
SinghIMorrisAP. Performance of transdermal therapeutic systems: effects of biological factors. Int J Pol Inf2011; 1: 4–9.
RohrUDEhrlyAMKuhlH. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women. Arzneimittelforschung1997; 47: 761–767.
21.
KraemerGRKraemerRROgdenBW, et al.Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril2003; 79: 534–542.
22.
JarvinenABäckströmAElfströmC, et al.Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Mauritas2001; 38: 189–196.
23.
BusterJE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expet Opin Pharmacother2010; 11: 1489–1499.
24.
MortonTLGattermeirDJPetersenCA, et al.Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. J Clin Pharmacol2009; 49: 1037–1046.
25.
GlynneSReiselDKamalA, et al.The range and variation in serum estradiol concentration in perimenopausal and postmenopausal women treated with transdermal estradiol in a real-world setting: a cross-sectional study. Menopause2025; 32: 103–111.
26.
SteingoldKALauferLChetkowskiRJ, et al.Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab1985; 61: 627–632.
27.
PanayNVersiESavvasM. A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy. Br J Obstet Gynaecol2000; 107: 1012–1016.
28.
YasuiTUemuraHTezukaM, et al.Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res2001; 56: 38–44.
29.
GarnettTStuddJWWHendersonA, et al.Hormone implants and tachyphylaxis. Br J Obstet Gynaecol1990; 97: 917–921.
30.
SmithRNStuddJWWZambleraD, et al.A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol1995; 102: 475–484.
31.
DupontADupontPCusanL, et al.Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas1991; 13: 297–311.
32.
ScottRTRossBAndersonC, et al.Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol1991; 77: 758–764.
WatsonJWhitingPFSalisburyC, et al.Blood tests in primary care: a qualitative study of communication and decision-making between doctors and patients. Health Expect2022; 25: 2453–2461.
35.
MakiPMGastMJViewegAJ, et al.Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology2007; 69: 1322–1330.
36.
El KhoudarySRGreendaleGCrawfordSL, et al.The menopause transition and women’s health at midlife: a progress report from the study of women’s Health across the nation (SWAN). Menopause2019; 26: 1213–1227.
37.
KlaiberELBrovermanDMVogelW, et al.Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology1997; 22: 549–558.
38.
BoardmanHMHartleyLEisingaA, et al.Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev2015; 3: CD002229.
GulamhuseinNMirandaKTAhmedSB, et al.Measurements of postmenopausal serum estradiol levels and cardiovascular events: a systematic review. CJC Open2023; 6: 347–354.
41.
MizunumaHTaketaniYOhtaH, et al.Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric2010; 13: 72–83.
42.
StuddJSavvasMWastonN, et al.The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol1990; 163: 1474–1479.
43.
de VilliersTJStevensonJC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric2012; 15: 263–266.
44.
EvansSFDavieMW. Low and conventional dose transdermal estradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol1996; 44: 79–84.
45.
ArmstonAWoodP. Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?Ann Clin Biochem2002; 39: 184–193.
46.
CauleyJA. Estrogen and bone health in men and women. Steroids2015; 99: 11–15.
47.
ZhuHJiangJWangQ, et al.Associations between ERα/β gene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMS Endocrine Disorders2018; 18: 11.
SaulHGursulDCassidyS, et al.Risk of breast cancer with HRT depends on therapy type and duration. BMJ2022; 376: o485.
50.
KaaksRRinaldiSKeyTJ, et al.Postmenopausal serum androgens, estrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer2005; 12: 1071–1082.
51.
FurnessSRobertsHMarjoribanksJ, et al.Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev2012; 2012: CD000402.
52.
VinogradovaYCouplandCHippisley-CoxJ. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ2019; 364: k4810.
53.
ESHRE Guideline Group on POIWebberLDaviesMAndersonR, et al.ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod2016; 31: 926–937.
54.
ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POIPanayNAndersonRABennieA, et al.Evidence-based guideline: premature ovarian insufficiency. Climacteric2024; 27: 510–520.
55.
JayasenaCNDevineKBarberK, et al.Society for Endocrinology guideline for understanding, diagnosing and treating female hypogonadism. Clin Endocrinol2024; 101: 409–442.
